BIOCHEETAH

BioCheetah is ISO 13485:2016 certified for design and development Medical device of its R&D facilities located in Singapore... BioCheetah Pte Ltd is a Singapore-based, A*STAR-IMCB spin-off diagnostics company. It is primarily set up to develop and commercialize non-invasive, protein-based immunodiagnostic applications. First diagnostic applications in development are based on the proprietary bladder cancer biomarkers and detection antibodies discovered and developed in IMCB. Both Intellectual Property of bladder cancer biomarkers and detection antibodies are exclusively licensed from A*STAR. Products to be developed include professional use in-vitro diagnostic VECanDx ELISA and Point-Of-Care Test (POCT) kits. The kits will employ a novel multiplex urine-based biomarkers panel with high sensitivity and specificity for diagnosis and monitoring of bladder cancer. BioCheetah's target markets are to encompass local and overseas public and private healthcare providers. In addition, clinical..

Also known as: BioCheetah Pte Ltd

Primary location: Singapore